The partnership combines AUM's discovery and clinical development capabilities with Newsoara's strong discovery, development, and manufacturing capabilities in China.
Under the terms of the Agreement, AUM will receive an undisclosed collaboration fee upon closing. AUM will license exclusive greater China rights of AUM001, AUM302 and AUM003 upon closing of this Agreement, and up to a further 3 candidates for a maximum of 6 oncology drugs.
AUM will receive up to USD 135m in near term development, regulatory, commercial milestones and up to double-digit royalty payments. Newsoara will be responsible for all development and commercialisation and will contribute for potential R and D funding for current and future investigational compounds in greater China.
AUM and Newsoara will co-discover and co-fund first-in-class therapeutics for mutually agreed novel targets.
AUM retains worldwide rights ex-greater China and Newsoara retains greater China rights for these newly discovered compounds.
Newsoara's CEO, Benny Li will join AUM's board of directors.
AUM is building a diverse portfolio of small molecule therapeutics that target critical biological pathways. A core component of AUM's strategy is mandating biomarkers and leveraging AI to systematically discover and develop targeted cancer therapies.
Additionally, AUM has a strong focus on the development of intra-portfolio combinations that include small molecules.
Through its "Asia to Global" Strategy, including this partnership, AUM will expedite drug development to meet unmet medical needs for patients globally.
AUM is a clinical-stage biopharmaceutical company with a focus on discovering, acquiring, and developing novel therapeutics in oncology. AUM utilizes AI-augmented platform to systematically discover and develop targeted cancer therapies focused on genetic targets.
Newsoara is a clinical-stage biopharmaceutical company with a mission to develop and commercialize life changing medicines for cancer, autoimmune, metabolic and other major diseases to patients in China and around the world.
Sanofi's rilzabrutinib granted US orphan drug designation for sickle cell disease
RemeGen secures approval in China for Telitacicept in treating generalised myasthenia gravis
Sanofi acquires DR-0201 from Dren Bio to expand immunology pipeline
InnoCare reports first patient dosed in Phase II/III vitiligo trial
Hemogenyx Pharmaceuticals expands HG-CT-1 trial to include paediatric AML patients
CARsgen reports positive preliminary clinical data for CT0596 in R/R MM
RTW Biotech portfolio company Jade Biosciences merges with Aerovate Therapeutics